Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Protalex has said that data from preclinical studies show that its PRTX-100 compound was as effective as the standard medication Enbrel in treating rheumatoid arthritis.
Subscribe to our email newsletter
In the studies, reduction in clinical scores and pathology with PRTX-100 were equivalent to the suppression seen in mice treated with etanercept. Etanercept is co-marketed by Amgen and Wyeth under the trade name Enbrel and is an FDA-approved treatment for rheumatoid arthritis. PRTX-100 was also able to delay onset and decrease severity of symptoms
The pre-clinical studies involved administering PRTX-100 into collagen-induced arthritis mouse models, which mirror many of the disease symptoms of rheumatoid arthritis, including polyarthritis, synovitis and caritage/bone erosions.
“We are encouraged by the results of the study, particularly because PRTX-100 demonstrated efficacy in the gold-standard model for evaluating rheumatoid arthritis therapies,” said Steven Kane, president and CEO of Protalex.